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15-Deoxy-12,14-prostaglandin J2 regulates mesangial cell prolif- Glomerular injury of diverse etiologies is accompanied
eration and death. by proliferation of intrinsic cells and infiltrating leuko-
Background. Proliferation of intrinsic glomerular cells is a cytes. Acutely, proliferation may afford certain benefits
common response to renal injury. Acutely, proliferation may
[1, 2]. For example, an increase in the number of mesan-be beneficial, but sustained glomerular hypercellularity after
gial cells during immune complex-mediated glomerulo-injury is associated with progressive renal failure. To identify
endogenous factors that may be responsible for regulating glo- nephritis (GN) may enhance the efficacy of immune com-
merular cell number, the effects of J-series cyclopentenone plex clearance from the glomerulus. During resolution
prostaglandins (PGs) on human glomerular mesangial cell pro- of glomerular disease a return to normal glomerular ar-
liferation and death were examined.
chitecture is necessary, and may be achieved as excessMethods. Human mesangial cells were grown in the pres-
cells undergo apoptosis [2]. Conversely, transition toence or absence of PGJ2 or its metabolite 15-Deoxy-12,14-PGJ2
chronic GN is often associated with a sustained increase(15dPGJ2). The number of viable cells was measured by the
reduction of the tetrazolium MTS to a colored formazan prod- in glomerular cellularity, which is almost certainly detri-
uct. Apoptosis was assessed by caspase-3 activation and DNA mental to glomerular function [1, 2]. Understanding the
fragmentation. endogenous factors responsible for regulating glomeru-Results. PGJ2 at concentrations up to 10mol/L caused mes- lar cell proliferation and cell death is necessary to identifyangial proliferation. 15dPGJ2 also caused mesangial prolifera-
molecular targets for treatment of chronic GN.tion at low concentrations (2.5 mol/L), but induced mesan-
gial cell death at higher concentrations (5mol/L). Cell death Prostaglandins have diverse effects on renal function,
occurred in part through apoptosis, measured as an increase in including regulation of glomerular hemodynamics, al-
caspase-3 activity and DNA fragmentation in 15dPGJ2-treated teration of tubular solute transport, and modulation of
cells. Cell death was associated with a decline in baseline phos- inflammation [3–5]. Cyclopentenone prostaglandins, par-phorylation of the survival factor Akt and increased Akt degra-
ticularly of the J-series, display several unique character-dation, whereas 15dPGJ2-induced mesangial proliferation was
istics that led us to speculate they may be involved inblocked by inhibition of the PI 3-kinase/Akt pathway. 15dPGJ2
is a potent PPAR agonist. Like 15dPGJ2, treatment of mesan- glomerular cell proliferation and apoptosis. Prostaglan-
gial cells with thiazolidinedione-type PPAR ligands (10 to 20 din J2 (PGJ2) is a dehydration product of prostaglandin
mol/L) caused significant cell death, but at lower concentra- D2 (PGD2) in aqueous environments [6, 7]. In the pres-tions also caused a small degree of proliferation.
ence of protein, PGJ2 is further non-enzymatically me-Conclusions. J-series prostaglandins thus may be involved
tabolized to 15-deoxy-12,14-prostaglandin J2 (15dPGJ2)in the initiation of glomerular hypercellularity through Akt-
[6, 7]. These novel prostaglandins readily form thiol con-dependent proliferation, and restoration of normal glomerular
architecture through PPAR-mediated apoptosis. Manipula- jugates with glutathione and cysteine because of electro-
tion of these prostaglandins may be relevant to the treatment philic carbons in their cyclopentenone rings [6]. Conjuga-
of progressive glomerular disease. tion with proteins may lead to modification of protein
function, especially if the active site of an enzyme is
affected. Furthermore, 15dPGJ2 is a potent agonist ofKey words: mesangial cell; cyclopentenone prostaglandin, peroxisome
peroxisome proliferator-activated receptor (PPAR)-proliferator-activated receptor, thiazolidinedione, glomerular hyper-
cellularity, apoptosis. [8]. PPAR is a ligand-activated nuclear receptor that
mediates the transcription of genes containing a peroxi-Received for publication August 7, 2001
some-proliferator response element, after heterodimeri-and in revised form November 26, 2001
Accepted for publication November 28, 2001 zation with ligand-activated retinoid X receptor- [9, 10].
PPAR is also the molecular target of the thiazolidinedi- 2002 by the International Society of Nephrology
1293
Rovin et al: J-series prostaglandins and mesangial survival1294
one (TZD) class of anti-diabetic agents [11]. In various inactivated fetal bovine serum (FBS; GIBCO, Grand
Island, NY, USA). Twenty-four hours before treatmenttransformed and normal cell types, 15dPGJ2 and TZDs
have been shown to variably induce proliferation or apo- the FBS in the media was reduced to 0.5%, and all
experiments were subsequently done in RPMI 1640 plusptosis [12–14]. It has been postulated that the effects of
15dPGJ2 on cell cycle are mediated by PPAR, and that 0.5% FBS.
Cells were treated as indicated, with prostaglandinsinduction of proliferation versus apoptosis depends on
the degree of PPAR activation [12]. (15dPGJ2, PGJ2, PGD2) as solutions in methyl acetate
(Cayman Chemical, Ann Arbor, MI, USA), the TZDsThe data from several recent reports suggest that the
J-series prostaglandins may play a role in glomerular ciglitazone or troglitazone in ethanol or dimethyl sulfox-
ide (DMSO), respectively (Biomol, Plymouth Meeting,pathology. Using human mesangial cells, we showed that
15dPGJ2 and PGJ2 block interleukin-1 (IL-1)–induced PA, USA), 9-cis retinoic acid (RA) in DMSO (Biomol),
or LY294002 in DMSO (Calbiochem, San Diego, CA,chemokine production and nuclear factor-B activation
(NF-B), and activate extracellular signal-related kinase USA). In each experiment the control cells were treated
with organic solvents in the same concentrations as cells[15, 16]. Despite establishing the existence of PPAR in
mesangial nuclei, our data did not support a role for treated with prostaglandins or TZDs. In experiments
where compounds prepared in different organic solventsPPAR in mediating these effects of 15dPGJ2 [15, 16].
In contrast, other investigators have shown that TZD were added to mesangial cells together (for example,
LY294002 in DMSO plus 15dPGJ2 in methyl acetate),treatment of animals with experimental diabetes, or non-
diabetic glomerulosclerosis reduced proteinuria, glomer- both solvents were given to control cells. The organic
solvents did not significantly affect mesangial viability,ular scarring, and glomerular matrix protein expression
[17–20]. In these studies, glomerular cell proliferation in measured as described below.
vitro in response to a growth factor, and in vivo in re-
Measurement of cell proliferation, growth arrest, andsponse to hyperfiltration-induced glomerular injury, was
cell deathattenuated by TZDs [19, 20].
The current investigation was undertaken to study the To assess mesangial cell proliferation and viability in
response to specific treatments, two thousand viable mes-effects of J-series prostaglandins on human mesangial
cell proliferation and death. The results demonstrated angial cells were seeded overnight into 96-well plates.
The following day the serum in the media was reduceddifferential effects of PGJ2 and 15dPGJ2 on mesangial
viability and growth. 15dPGJ2 induced mesangial prolif- to 0.5%. After 24 hours, media containing test reagents
or their vehicles was added to cells, also in 0.5% serum.eration at low concentrations, but caused cell death at
least in part through apoptosis at high concentrations. The cells were incubated another 18 to 24 hours, after
which 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-Conversely, PGJ2 and the parent prostaglandin PGD2
induced mesangial proliferation throughout the concen- yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and
phenazine ethosulfate were added for 90 minutes (Cell-tration range examined. Treatment with TZDs (plus or
minus the retinoid X receptor agonist 9-cis retinoic acid) Titer 96; Promega Corp., Madison, WI, USA). Absorb-
ance recorded at 490 nm represented the reduction ofalso caused mesangial death, suggesting that 15dPGJ2-
mediated apoptosis may occur through PPAR. Inhib- MTS to a formazan product, and linearly correlated with
the number of living cells present in each well. Data areiting the constitutive activity of the pro-survival factor
Akt blocked prostaglandin-induced mesangial prolifera- reported as a proliferation index, calculated as the ratio
of absorbance for a specific treatment to the absorbancetion, whereas concentrations of 15dPGJ2 that cause cell
death were associated with dephosphorylation and deg- of control (vehicle-treated) cells. In this way, the control
condition always has a proliferation index of 1. A prolif-radation of Akt. These data indicate that J-series prosta-
glandins have selective effects on mesangial cell growth eration index greater than 1 represents a gain of cells
compared to control (cell proliferation), while an indexand survival that may be relevant to the pathogenesis
and treatment of chronic GN. below 1 represents loss of cells compared to control (cell
death).
METHODS Detection of Akt and phospho-Akt
Human mesangial cell culture and treatment After the indicated treatments, mesangial cells (both
floating and adherent) were rapidly lysed in sodium do-Human mesangial cells were cultured from adult kid-
neys not suitable for transplantation, and were character- decyl sulfate (SDS) lysis buffer [4% SDS, 1 mmol/L
ethylenediaminetetraacetic acid (EDTA), 1 mmol/Lized as we have previously described [21]. Cells from at
least three different donors were used between passages phenylmethylsulfonyl fluoride (PMSF), 20 mol/L leupep-
tin, and 0.15 U/mL aprotinin). Cell lysates were briefly4 and 7. Unless otherwise indicated, cells were grown to
80% confluence in RPMI 1640 containing 10% heat- sonicated at 4	C and equivalent amounts promptly sepa-
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rated on SDS-polyacrylamide gels under reducing condi- meter (Becton Dickinson, Mountain View, CA, USA)
using ModFit LT software (Verity Software, Topsham,tions. Proteins were transferred to nitrocellulose and the
membranes were probed overnight at 4	C with rabbit ME, USA) to determine the percent of apoptotic (hypo-
diploid) cells.polyclonal anti-phospho Akt (New England Biolabs,
Beverly, MA, USA). This antibody recognizes Akt that DNA fragmentation also was detected by DNA lad-
dering. DNA was extracted from 4 
 106 mesangial cellshas been phosphorylated at serine473, a requirement for
activation of Akt [22]. Equivalent amounts of lysate also (floating and adherent) after appropriate treatment.
DNA ladders were visualized using a polymerase chainwere immunoblotted with a goat polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) that reaction (PCR)-based technique, according to manufac-
turer’s instructions (ApoAlert LM-PCR ladder assay kit;recognizes total Akt.
Clontech, La Jolla, CA, USA).
Detection of apoptosis
Statistical analysisBecause the MTS assay does not identify mechanisms
behind a decline in proliferation index (see above), addi- Data are presented as the mean  standard error of
the mean, unless otherwise indicated. Multiple compari-tional studies were undertaken to investigate whether
apoptosis plays a role in the observed 15dPGJ2-induced sons were examined for significant differences using anal-
ysis of variance (ANOVA), followed by individual com-decrease in mesangial proliferation. As an indication of
apoptosis, caspase-3 activation was examined using an parisons with the Bonferroni post-test. Comparisons
between two groups were made with the Student t test.enzymatic caspase assay we have previously described
[23]. Briefly, lysates from 3 
 106 mesangial cells treated A P  0.05 was considered significant.
with vehicle, 15dPGJ2, or ciglitazone were prepared by
four cycles of freeze thawing after collecting the cells
RESULTS
(both floating and adherent) in KPM buffer [50 mmol/L
Proliferative and cytotoxic effects of J-seriesKCl, 50 mmol/L PIPES, 10 mmol/L EGTA, 1.92 mmol/L
prostaglandins on human mesangial cellsMgCl2, pH 7.0, 1 mmol/L dithiothreitol (DTT), 0.1
mmol/L PMSF, 10g/mL cytochalasin B, and 2g/mL of After treatment of cultured mesangial cells with vari-
ous concentrations of 15dPGJ2 or PGJ2 for 18 hours,the protease inhibitors chymostatin, pepstatin, leupeptin,
and antipain]. These lysates were incubated with 20 the number of living cells was determined by measuring
cellular reduction of a tetrazolium compound (MTS) tomol/L Asp-Glu-Val-Asp-amino trifluoromethyl cou-
marin (DVED-AFC) in a buffer containing 10% glyc- a formazan product. As shown in Figure 1A, 15dPGJ2
induced mesangial cell proliferation or cell death, de-erol, 50 mmol/L PIPES, pH 7, 1 mmol/L EDTA, and 1
mmol/L DTT. DVED-AFC is a fluorogenic substrate for pending on its concentration. Between 1 and 2.5 mol/L
15dPGJ2, mesangial MTS reduction increased 66 to 78%,caspase-3 family enzymes. Release of free AFC from
DVED-AFC over time reflects caspase-3 activity, and respectively. This pro-proliferative effect was abolished
at higher levels of 15dPGJ2, and concentrations betweenwas determined using a Cytofluor 4000 fluorometer (fil-
ters were excitation, 400 nm, and emission, 505 nm; Per- 7.5 and 10 mol/L were cytotoxic, causing a 50 to 60%
decrease in MTS reduction (Fig. 1A). No decrease inseptive Diagnostics, Framingham, MA, USA). Thirty
time points were measured per condition. Caspase-3 ac- MTS reduction was seen if cells were incubated with 10
mol/L 15dPGJ2 for only six hours. In contrast, PGJ2 intivity was normalized to cell protein, and expressed as
pmol AFC released per minute per mg protein. concentrations from 5 to 10 mol/L induced a degree of
mesangial proliferation similar in magnitude to 1 to 2.5DNA fragmentation also was used as an indication of
mesangial apoptosis. Cells were treated as indicated, and mol/L 15dPGJ2 (Fig. 1B). Incubation with 25 mol/L
PGJ2 did not cause cell death, and 50 mol/L PGJ2 onlyboth floating and adherent cells were harvested, washed
in phosphate-buffered saline (PBS), and fixed in ice-cold caused a 30% decline in MTS reduction (data not
shown). Similarly, mesangial cells treated with PGD2,70% ethanol (1 
 106 cells/mL, 20	C) overnight. After
fixation, cells were washed, incubated in 0.2 mol/L the prostaglandin precursor of PGJ2, proliferated in re-
sponse to concentrations of 10 to 50 mol/L (Fig. 1C).Na2HPO4–0.004 mol/L citric acid buffer, pH 7.8, for 10
minutes at room temperature, and then resuspended in
Cytotoxic effects of a TZD PPAR agonist onPBS containing 0.1% Triton X-100 and 10 U/mL of
mesangial cellsDNase-free RNase A (10 min, 37	C). This protocol ex-
tracted low molecular weight DNA from apoptotic cells 15dPGJ2 is a potent agonist of PPAR. Because hu-
man mesangial cells express PPAR, it is conceivablebut did not affect the DNA content of non-apoptotic
cells [24]. Cells were then stained with propidium iodide that the effects of 15dPGJ2 may be mediated by PPAR.
To examine this possibility, mesangial cells were treated(25 g/mL) for a minimum of two hours at 4	C, and
DNA content analyzed on a FACSCalibur flow cyto- for 18 hours with ciglitazone or troglitazone, TZD
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Fig. 1. Mesangial cell proliferation and death in response to prostaglan-
dins. Mesangial cells were incubated with the indicated concentrations
of prostaglandins for 18 hours. Cell viability was assessed by MTS
reduction, and the proliferation index calculated as described in Meth-
ods section. (A) Dose-dependent effect of 15-deoxy-12,14-prostaglandin
J2 (15dPGJ2) on mesangial viability. Each point represents the mean
of at least 4 individual experiments done in quadruplicate. *P  0.01
vs. control cells. (B) Dose-dependent effect of prostaglandin J2 (PGJ2)
on mesangial viability. Each point represents the mean of at least 4
individual experiments done in quadruplicate. *P  0.001 vs. control
cells. (C) The dose-dependent effect of prostaglandin D2 (PGD2) on
mesangial viability is shown. Each point represents the mean of 3
individual experiments done in quadruplicate. *P  0.001 vs. control
cells.
PPAR agonists, and cell viability was measured. As The TZD plus RA results suggested that the antiprolif-
erative effects of 15dPGJ2 also could be mediatedshown in Figure 2A, ciglitazone induced mesangial cell
through PPAR. When RA (10 mol/L) was added todeath at concentrations greater than 10 mol/L. There
cells treated with concentrations of 15dPGJ2 that arewas a small increase in proliferation index (21%) in re-
proliferative (1 to 2.5 mol/L) or growth-neutral (5sponse to 5 mol/L ciglitazone, but this did not reach
mol/L), the mesangial proliferation index fell signifi-significance. Similar results were found when troglita-
cantly (Fig. 2C). Cell death was observed when RA waszone was used (Fig. 2B). Cell death occurred at concen-
added to 2.5 and 5 mol/L 15dPGJ2, and proliferationtrations greater than 15 mol/L, and there was a small,
was blocked in cells treated with 1 mol/L 15dPGJ2 plusbut significant increase in proliferation index (18%) us-
RA (Fig. 2C).ing 10 mol/L troglitazone.
9-Cis retinoic acid (RA) is a ligand for the retinoid X
Phosphatidylinositol 3-kinase inhibition attenuatesreceptor (RXR). After ligand binding, RXR hetero-
15dPGJ2-induced mesangial proliferationdimerizes with ligand-activated PPAR and activates
genes that contain a peroxisome proliferator response The serine/threonine kinase Akt/PKB appears to pro-
vide a cell survival/proliferation signal for many cell typeselement. Consistent with the antiproliferative effect of
ciglitazone and troglitazone being mediated through [22]. A regulatory role for Akt in the response of mesan-
gial cells to 15dPGJ2 was investigated by treating thePPAR, ciglitazone and troglitazone-induced cell death
was significantly enhanced when mesangial cells were cells with the phosphatidylinositol 3-kinase (PI 3-kinase)
inhibitor LY294002 before incubation with a pro-prolif-simultaneously treated with 10 mol/L RA (Fig. 2 A,
B). RA alone at this concentration had no significant erative concentration (1mol/L) of 15dPGJ2. PI 3-kinase
is an upstream enzyme in the pathway that results ineffect on mesangial viability (proliferation index of 1.09
0.03, N  4). phosphorylation and activation of Akt. LY294002 (10
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Fig. 2. Cytotoxicity of peroxisome proliferator-activated receptor-
(PPAR) agonists for human mesangial cells. Mesangial cells were
treated with the indicated concentrations of thiazolidinediones (TZDs)
or prostaglandin in the presence (dotted line) or absence (solid line)
of 10 mo/L 9-cis retinoic acid (RA) for 18 hours. Cell viability was
assessed by MTS reduction, and the proliferation index calculated as
described in Methods section. Each point represents the mean of at
least 3 individual experiments done in quadruplicate. (A) The dose-
dependent effect of ciglitazone on mesangial viability (*P  0.001,
**P  0.05 vs. control cells). (B) The dose-dependent effect of troglita-
zone on mesangial viability (*P  0.01, **P  0.001 vs. control cells).
(C) The effect of RA plus 15dPGJ2 on mesangial viability (*P  0.001
vs. control cells, **P 0.01 vs. cells treated with 15dPGJ2 in the absence
of RA). Symbols are: () RA; ( ) RA.
mol/L) had no effect on mesangial viability alone, but phorylation (Fig. 4A). Treatment with 1mol/L 15dPGJ2
it completely blocked cell proliferation in response to for 1,4, 6, or 18 hours did not affect Akt phosphorylation
15dPGJ2 (Fig. 3). LY294002 also attenuated PGJ2-medi- (6 and 18 hour time points shown in Fig. 4 B, C). Con-
ated mesangial proliferation (data not shown). The anti- versely, higher concentrations of 15dPGJ2 caused a dose-
Akt activity of LY294002 in human mesangial cells was dependent decline in both phospho-Akt and total Akt
verified by immunoblotting for phospho-Akt, as illus- levels (Fig. 4 B, C). Phospho-Akt was almost undetect-
trated in Figure 4A (discussed below). able after incubation with 10 mol/L 15dPGJ2 for six or
Akt was constitutively phosphorylated in human mes- more hours. In cells incubated with 10 mol/L 15dPGJ2,angial cells under the conditions of these experiments immunoreactive Akt moderately decreased after six
(Fig. 4A). This basal phosphorylation was not due to
hours, and largely disappeared after 18 hours of treat-serum withdrawal, as cells cultured in both serum-free
ment. The loss of Akt during prolonged treatment withand serum-replete media demonstrated similar levels of
a cytotoxic dose (10 mol/L) of 15dPGJ2 was not dueAkt phosphorylation (data not shown). Despite this base-
to a general degradation of cellular proteins. As shownline phosphorylation, interleukin-1 (IL-1) a known
in Figure 5, there was no difference in the Coomassie-activator of Akt [25, 26], further increased serine phos-
stained protein pattern from the same lysates used forphorylation of Akt (Fig. 4A). LY294002 (10 mol/L)
immunoblotting phospho- and total Akt (Fig. 4). In con-completely blocked basal Akt phosphorylation, and sig-
nificantly inhibited the IL-1–induced increase in phos- trast, PGJ2 (1 to 10 mol/L), which does not cause sig-
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treated controls. Consistent with this result, nucleosomal
ladder formation was observed in DNA isolated from
cells treated with 10 mol/L 15dPGJ2 for 18 hours (data
not shown).
DISCUSSION
Proliferation of glomerular cells may be an initial
adaptive response to glomerular injury, but sustained
proliferation is often associated with, and probably con-
tributes to, a progressive decline in renal function [1, 2].
In an effort to understand potential endogenous mecha-
nisms that regulate glomerular cellularity, we examined
the effects of J-series cyclopentenone prostaglandins on
human mesangial cell proliferation and death in an ex
vivo model. It was found that both PGJ2 and 15dPGJ2
Fig. 3. Phosphatidylinositol 3 (PI 3)-kinase pathway inhibition abro- induce mesangial proliferation. Interestingly, 15dPGJ2gates mesangial proliferation in response to 15dPGJ2. Cells were treated
also causes mesangial cell death, in part through apopto-with solvent alone (control) or 15dPGJ2 (1 mol/L) in the presence or
absence of LY294002 (10 mol/L) for 18 hours. LY294002 was added sis. These seemingly disparate effects of 15dPGJ2 are
1 hour before 15dPGJ2. Cell viability was measured by MTS reduction, concentration dependent, with doses of 15dPGJ2 greaterand the proliferation index calculated as described in the Methods
than 5 mol/L activating an apoptotic program. Mesan-section. The data represent the mean of 5 individual experiments done in
quadruplicate. *P 0.01 vs. control; **P 0.05 15dPGJ2 vs. 15dPGJ2  gial proliferation in response to 15dPGJ2 and PGJ2 ap-
LY294002; P  0.05 15dPGJ2  LY294002 vs. control. pears to require a basal level of activity of the pro-
survival factor Akt, whereas cell death induced by higher
15dPGJ2 concentrations is associated with loss of Akt.
Because 15dPGJ2 activates PPAR, mesangial cells alsonificant mesangial cell death, did not affect Akt phos-
were treated with TZD-type PPAR agonists. TZDsphorylation, even after 18 hours of exposure (Fig. 4D).
mainly induce cell death, but can cause mild cell prolifer-
15dPGJ2 induces apoptosis of human mesangial cells ation, depending on their concentration. This suggests
that the effects of 15dPGJ2 on mesangial viability areMesangial cells treated with cytotoxic concentrations
mediated, in part, through PPAR.of 15dPGJ2 for 18 hours demonstrated morphologic
Concentration-dependent induction of cell prolifera-changes that included a rounded appearance and mem-
tion and apoptosis by 15dPGJ2 has been described inbrane blebs, and were easily detached from the tissue
several malignant cell lines [12]. Consistent with ourculture plates. These changes suggested that apoptosis
observations, cancer cells proliferated in response to con-could be the mechanism of cell death in response to
centrations of 15dPGJ2 up to 1 mol/L, and underwent15dPGJ2. To test this possibility, the activity of caspase-3
apoptosis after treatment with 15dPGJ2 in the 10 mol/Lwas measured in lysates of cells incubated with 15dPGJ2.
range [12]. Cell type also appears to influence the re-After 18 hours of treatment with 15dPGJ2 (10 mol/L),
sponse to 15dPGJ2. For example, it has been reportedmesangial cell lysates demonstrated a tenfold increase
that neural cells and rodent mesangial cells did not prolif-in caspase-3-like activity compared to untreated cells
erate to low concentrations of 15dPGJ2 [27–29].(P  0.01, N  4), and a fourfold increase in activity
It is not immediately clear why concentrations of PGJ2(P 0.05, N 4) compared to cells treated with 15dPGJ2
and PGD2 equal to or greater than 10 mol/L did notfor six hours (Fig. 6). Similarly, ciglitazone (25 mol/L)
cause mesangial cell death, but continued to induce pro-caused a ninefold increase in caspase-3–like activity after
liferation. A possible explanation for this finding is the18 hours of treatment compared to control cells (P 
presence of two electrophilic carbons in 15dPGJ2, com-0.001, N  4), and a fivefold increase (P  0.01) com-
pared to one reactive carbon in PGJ2 [30]. It is conceiv-pared to cells treated with ciglitazone for six hours (Fig. 6).
able that this may enhance the cytotoxicity of 15dPGJ2DNA fragmentation suggestive of apoptosis also was
by decreasing the threshold concentration needed to acti-detected in mesangial cells treated with 15dPGJ2. The
vate low abundance apoptotic mediators. Again, cellpercentage of hypodiploid (apoptotic) cells was quanti-
type appears to contribute to this differential sensitivityfied by flow cytometry after ethanol fixation, extraction
of small DNA fragments, and propidium iodide staining. to 15dPGJ2, PGJ2, and PGD2. Neuroblastoma cells
treated with PGJ2 or PGD2, at concentrations similar toAs shown in Figure 7, 12 to 18 hours of exposure to
15dPGJ2 induced a 2.5- to 3.5-fold increase in the popula- those used in our study, demonstrated a significant loss
of viability [28].tion of apoptotic mesangial cells compared to solvent-
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Fig. 4. Akt expression in prostaglandin-treated
mesangial cells. Mesangial cells were treated
with the indicated concentrations of 15dPGJ2
or PGJ2 for 6 or 18 hours. Interleukin-1
(IL-1; 1.1 ng/mL for 1 h) was used as a
positive control for Akt activation. In some
experiments cells were pre-incubated with
LY294002 (LY; 10 mol/L) or its vehicle
DMSO for one hour. Whole cell lysates were
immunoblotted for serine-phosphorylated Akt
with a specific anti-phospho serine473 Akt anti-
body, as well as for total Akt. The data are
representative of 5 individual experiments using
15dPGJ2 and 3 individual experiments using
PGJ2 or IL-1.
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Fig. 5. Whole cell protein profile of mesangial cells treated with
15dPGJ2. The lysates used for Akt immunoblotting (Fig. 4) were applied
in the same amounts to 8% polyacrylamide gels. The gels were stained
with Coomassie blue. Representative gels using lysates from cells Fig. 7. 15dPGJ2 induces mesangial DNA fragmentation. Mesangial
treated with the indicated concentrations of 15dPGJ2 for 6 and 18 hours cells were treated with vehicle alone ( ) or 15dPGJ2 () for the indi-
are shown. cated periods of time. DNA fragmentation was measured by flow cytom-
etry after ethanol fixation and extraction of low molecular weight DNA
from apoptotic cells. The portion of apoptotic (hypodiploid) cells was
calculated. Data represent the mean of 3 experiments. *P  0.05 and
**P  0.01 vs. control.
ity of 15dPGJ2. Together with the results of TZD treat-
ment, these data suggest a role for PPAR-dependent
gene transactivation in 15dPGJ2-induced cell death. This
does not however, exclude a PPAR-independent con-
tribution to the cytotoxicity of 15dPGJ2, as has been
postulated for 15dPGJ2-mediated macrophage apoptosis
[14].
Unlike 15dPGJ2, low concentrations of TZDs did not
induce robust mesangial proliferation, but caused only
a small increase in proliferation index. Furthermore, ad-
dition of RA to proliferative concentrations of 15dPGJ2
blocked mesangial proliferation. One interpretation of
these data is that 15dPGJ2-mediated mesangial prolifera-
Fig. 6. 15dPGJ2 and ciglitazone induce caspase-3 activation in human tion is PPAR-independent. Alternatively, low concen-
mesangial cells. Mesangial cells were treated with vehicle alone or the
trations of 15dPGJ2, in the absence of an RXR-activatingindicated concentrations of 15dPGJ2 or ciglitazone for either 6 ( ) or 18
() hours. The ability of cell lysates to release AFC from the fluorogenic signal, may cause a low level of PPAR activation that
caspase-3 substrate DVED-AFC was measured. The data represent the supports cell proliferation. Evidence for such a mecha-mean of 4 individual experiments. *P  0.01 vs. control and  0.05 vs.
nism is provided by studies that measured cell viability15dPGJ2-6 hours, **P  0.001 vs. control and  0.01 vs. ciglitazone-6
hours. and PPAR activity in response to 15dPGJ2 or a TZD.
These investigations demonstrated an association be-
tween the degree of PPAR activation and cell prolifera-
tion or cell death [12, 31]. Weak PPAR activation re-Because PPAR is a target of 15dPGJ2 and a transcrip-
sulted in cell proliferation, while strong activationtion factor, it is conceivable that 15dPGJ2 affects mesan-
correlated with cell death [12, 31].gial viability through a PPAR-dependent gene(s). The
The PI 3-kinase/Akt pathway appears to be involvedobservation that TZDs are cytotoxic, especially in combi-
in the survival of a variety of cell types [22]. Elimina-nation with RA, supports the possibility that PPAR-
tion of basal mesangial Akt phosphorylation with a PIactivated genes can mediate mesangial cell death. These
3-kinase inhibitor abrogated proliferation in response todata are consistent with studies that demonstrated TZD
15dPGJ2 and PGJ2. However, using pro-proliferativetreatment prevents glomerular cell proliferation after
renal injury in vivo [20]. RA also enhanced the cytotoxic- concentrations, neither prostaglandin increased Akt phos-
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phorylation above baseline. This suggests that a basal leukocytes increase local prostaglandin levels [35], the
prostaglandin balance may shift toward 15dPGJ2. Thislevel of active Akt is necessary for J-series prostaglandin-
induced mesangial proliferation, but that proliferation would favor the death of proliferated glomerular cells
and infiltrating leukocytes [14], resulting in restorationdoes not occur through direct activation of this pathway.
In support of this, IL-1 at a concentration that enhances of normal glomerular architecture. Individuals destined
to develop chronic glomerulonephritis may not achieveAkt phosphorylation (1.1 ng/mL; Fig. 4) did not induce
mesangial proliferation (proliferation index of 1.08  an intraglomerular prostaglandin balance that promotes
apoptosis. This model assumes that J-series prostaglan-0.05, N  4, unpublished observation). The intracellular
signals mediating proliferation in response to J-series dins are expressed in vivo during the course of glomeru-
lar disease. It should be noted that currently, there isprostaglandins remain unknown, and under investiga-
tion. no evidence that local concentrations of cyclopentenone
prostaglandins can reach levels comparable to those usedConversely, treatment with cytotoxic concentrations
of 15dPGJ2 caused a dose-dependent decline in Akt in this investigation. The assumption that J-series prosta-
glandins are expressed in the kidney is based on dataphosphorylation by six hours that exceeded loss of total
Akt protein. By 18 hours of treatment there was signifi- that rodent mesangial cells produce PGD2 and PGJ2 in
response to stimuli such as IL-1 [36, 37], and that ancant degradation of Akt. This cleavage of Akt appears
to be specific, to the extent that 15dPGJ2 did not cause intermediate metabolite between PGJ2 and 15dPGJ2,12-
PGJ2, is found in normal human urine [38]. 15dPGJ2generalized cell protein degradation, even at concentra-
tions that induced significant mesangial apoptosis. Loss itself has been very difficult to measure, and there is
only one report that detected it in vivo [39]. Clearly, inof Akt phosphorylation and Akt degradation probably
occur by two different mechanisms. It has been postu- testing the proposed model, an important issue will be
to verify glomerular PGJ2 and 15dPGJ2 production. Iflated that 15PGJ2 can inactivate protein kinases by conju-
gation to critical cysteines in the kinases via its cyclopen- J-series prostaglandins are not endogenous regulators of
glomerular cell growth and viability, the results of thetenone ring [30, 32]. In this way, 15dPGJ2 could inhibit
a kinase upstream of Akt, such as 3-phosphoinositide- current investigation demonstrate that mesangial cells
do respond to exogenous J-series prostaglandins, anddependent protein kinase, and attenuate the level of
active Akt. PI 3-kinase does not appear to be the direct suggest their potential role in the treatment of chronic
glomerulonephritis.target of 15dPGJ2 in mesangial cells, given our recent
observation that LY294002 blocks 15dPGJ2-induced ex-
tracellular regulated kinase activation [16]. On the other ACKNOWLEDGMENTS
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